Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905652 | 0.67 | — | — | |
| SCHEMBL2664153 | 0.62 | USP2 (0.34) | USP2LMNA | |
| SCHEMBL19069350 | 0.62 | USP2 (0.34) | USP2LMNA | |
| SCHEMBL7165116 | 0.60 | — | — | |
| SCHEMBL14564028 | 0.60 | USP2 (0.49) | USP2LMNA | |
| SCHEMBL14183118 | 0.60 | USP2 (0.49) | USP2LMNA | |
| SCHEMBL126552 | 0.60 | — | — | |
| SCHEMBL12389693 | 0.60 | — | — | |
| SCHEMBL14751607 | 0.59 | — | — | |
| SCHEMBL10033709 | 0.59 | USP2 (0.47) | USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296678-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | claimed |
| JP-2002509120-A | — | — | 2002-03-26 | — | — | JP | claimed |
| WO-2001098294-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1131306-A2 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1091945-A1 | CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-04-18 | — | — | EP | claimed |
| EP-1054871-A2 | PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-11-29 | — | — | EP | claimed |
| EP-1049693-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-11-08 | — | — | EP | claimed |
| EP-1042002-A1 | PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION | Du Pont Pharmaceuticals Company (US) | 2000-10-11 | — | — | EP | claimed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000029406-A2 | NOVEL ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000000481-A1 | CYCLIC CARBAMATES AND ISOXAZOLIDINES AS IIB/IIIA ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | claimed |
| WO-1999050249-A2 | PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| EP-0939757-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Dupont Pharmaceuticals Company (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1999036096-A1 | PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-22 | — | — | WO | claimed |
| WO-1999026945-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-06-03 | — | — | WO | claimed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| EP-1161279-A1 | TREATMENT OF THROMBOSIS BY COMBINED USE OF A FACTOR XA INHIBITOR AND ASPIRIN, TISSUE PLASMINOGEN ACTIVATOR (TPA), A GPIIB/IIIA ANTAGONIST, LOW MOLECULAR WEIGHT HEPARIN OR HEPARIN | Du Pont Pharmaceuticals Company (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0730590-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |